Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
T. Ivanushkina, S. Borisov, N. Litvinova, Y. Garmash (Moscow, Russian Federation). The individual-tailored treatment regimens for multidrug-resistant tuberculosis. Eur Respir J 2012; 40: Suppl. 56, 3329

Member's Comments

No comment yet.

Related content which might interest you: Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 The efficacy of a rifabutin-containing regimen for rifabutin-susceptible multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J, 53 (1) 1801154; 10.1183/13993003.01154-2018 Year: 2019 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings Source: Eur Respir J, 59 (1) 2004345; 10.1183/13993003.04345-2020 Year: 2022 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Linezolid in multidrug-resistant tuberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 485s Year: 2004 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Management and treatment of multidrug-resistant tuberculosis Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management Year: 2019 High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen Source: Eur Respir J, 52 (6) 1801528; 10.1183/13993003.01528-2018 Year: 2018 Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis Source: Annual Congress 2009 - Priorities in tuberculosis research Year: 2009 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001 Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 The efficiency of including the II-line drugs to the treatment regimen of isoniazid-resistant tuberculosis. Source: International Congress 2017 – MDRTB: detection and management Year: 2017